As Pfizer slashes revenue projections, Moderna says it “remains comfortable”

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with the latest twist in the GLP-1 saga, some drama in the world of Covid-19 booster shots, and the debut of the 2023 STAT Wunderkinds.

The need-to-know this morning
• Gilead Sciences and Assembly Biosciences announced a research partnership to develop new medicines for serious viral diseases, with an initial focus on herpesviruses, hepatitis B, and hepatitis D. Under terms of the agreement, Assembly will receive $100 million from Gilead, including an equity investment.
• Johnson & Johnson reported third-quarter adjusted earnings of $2.66 per share, beating Wall Street’s consensus estimate. Revenue for the quarter was $21.35 billion, an increase of 6.8% year over year. Of note, sales of Carvykti, J&J’s CAR-T treatment for multiple myeloma co-marketed with Legend Biotech, were $152 million, surpassing analyst expectations.
• Privately held SpliceBio signed a research partnership and licensing agreement with Spark Therapeutics, a division of Roche, to develop a gene therapy targeting an inherited eye disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In